Trials / Completed
CompletedNCT05258110
A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood
The Effect of Multiple Oral Doses of BI 425809 on Metabolism of Midazolam Administered Orally in Healthy Male Subjects (Open-label, Two-period, One-sequence Trial)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
In order to assess the potential impact of steady state BI 425809 on CYP3A clinically, the effect of BI 425809 on the midazolam pharmacokinetics will be evaluated. Midazolam is a recommended substrate of CYP3A4.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | midazolam | midazolam |
| DRUG | iclepertin (BI 425809) | BI 425809 |
Timeline
- Start date
- 2022-03-18
- Primary completion
- 2022-05-31
- Completion
- 2022-05-31
- First posted
- 2022-02-28
- Last updated
- 2026-03-30
- Results posted
- 2026-03-30
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05258110. Inclusion in this directory is not an endorsement.